Center for Medicine in the Public Interest
Encyclopedia
The Center for Medicine in the Public Interest (CMPI) is a non-profit medical issues research group that is partially funded by the pharmaceutical industry. According to the its critics, it "was originally a project of the Pacific Research Institute
, an older corporate front established in conjunction with Philip Morris
to fabricate academic support for the tobacco industry." CMPI's agenda is research driven and deals with clinical outcomes and econometric studies that analyze the value of new medicines and genomic and molecular-based medical innovation. It claims to do this from the consumer's perspective.
CMPI is a 501(c)3 organization and as such is not permitted to devote a substantial part of its activity to lobbying, but its officers have written articles on various issues including price controls on pharmaceutical products in publicly funded healthcare schemes in the United States
, and restrictions on advertising in the European Union
. The Economist Intelligence Unit has claimed that the organisation generally takes a pro-drug industry viewpoint.
administration, and Dr. Robert Goldberg, former fellow at the Manhattan Institute.
CMPI Senior Fellows include:
Alzheimer's treatments, evidence-based medicine, drug counterfeiting and healthcare terrorism.
Pacific Research Institute
The Pacific Research Institute , or officially the Pacific Research Institute for Public Policy, is a California-based free-market think tank founded in 1979 whose stated vision is the promotion of "the principles of individual freedom and personal responsibility"...
, an older corporate front established in conjunction with Philip Morris
Philip Morris USA
Philip Morris USA is the United States tobacco division of Altria Group, Inc. Philip Morris USA brands include Marlboro, Virginia Slims, Benson and Hedges, Merit, Parliament, Alpine, Basic, Cambridge, Bucks, Dave's, Chesterfield, Collector's Choice, Commander, English Ovals, Lark, L&M, Players and...
to fabricate academic support for the tobacco industry." CMPI's agenda is research driven and deals with clinical outcomes and econometric studies that analyze the value of new medicines and genomic and molecular-based medical innovation. It claims to do this from the consumer's perspective.
CMPI is a 501(c)3 organization and as such is not permitted to devote a substantial part of its activity to lobbying, but its officers have written articles on various issues including price controls on pharmaceutical products in publicly funded healthcare schemes in the United States
United States
The United States of America is a federal constitutional republic comprising fifty states and a federal district...
, and restrictions on advertising in the European Union
European Union
The European Union is an economic and political union of 27 independent member states which are located primarily in Europe. The EU traces its origins from the European Coal and Steel Community and the European Economic Community , formed by six countries in 1958...
. The Economist Intelligence Unit has claimed that the organisation generally takes a pro-drug industry viewpoint.
Personnel
CMPI was founded by Peter Pitts, former FDA Associate Commissioner for External Relations under the BushGeorge W. Bush
George Walker Bush is an American politician who served as the 43rd President of the United States, from 2001 to 2009. Before that, he was the 46th Governor of Texas, having served from 1995 to 2000....
administration, and Dr. Robert Goldberg, former fellow at the Manhattan Institute.
CMPI Senior Fellows include:
- Marc Siegel, MD (A contributor to FoxNews)
- Doug Badger
- John F. P. Bridges
- Jacob Arfwedson
Funding
- PhRMA - the pharmaceutical industry trade group
- PfizerPfizerPfizer, Inc. is an American multinational pharmaceutical corporation. The company is based in New York City, New York with its research headquarters in Groton, Connecticut, United States...
- the world's largest drug company
Reports
CMPI has published studies on the value of new cancer drugs, the cost-effectiveness of certainAlzheimer's treatments, evidence-based medicine, drug counterfeiting and healthcare terrorism.